Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2026)
Caribou Biosciences (CRBU) reported Income from Continuing Operations of 26280000.0 for Q1 2026, up 38.76% year-over-year from 18939200.62 in Q1 2025, and up 7.64% quarter-over-quarter from 28453000.0 in Q4 2025.
Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of Income from Continuing Operations data on file, last reported at 26280000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 26280000.0, up 38.76% year-over-year; the trailing twelve-month figure through Mar 2026 was 131711000.0 (up 19.46% YoY), and the FY2025 annual result was 148125000.0, up 0.66% from the prior year.
- Income from Continuing Operations improved to 26280000.0 in Q1 2026 per CRBU's latest filing, from 28453000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 14633000.0 in Q3 2023 and troughed at 47578000.0 in Q2 2025.
- A 5-year average of 33158705.88 and a median of 31116000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 44.86% in 2023, then slumped 161.31% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 30578000.0 in 2022, then slipped by 22.45% to 37442000.0 in 2023, then dropped by 3.83% to 38875000.0 in 2024, then advanced by 26.81% to 28453000.0 in 2025, then increased by 7.64% to 26280000.0 in 2026.
- Business Quant data shows CRBU's Income from Continuing Operations at 26280000.0 in Q1 2026, 28453000.0 in Q4 2025, and 29400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - | -26.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.28 Mn |
| Dec 31, 2025 | -28.45 Mn |
| Sep 30, 2025 | -29.40 Mn |
| Jun 30, 2025 | -47.58 Mn |
| Mar 31, 2025 | -42.91 Mn |
| Dec 31, 2024 | -38.88 Mn |
| Sep 30, 2024 | -38.24 Mn |
| Jun 30, 2024 | -43.50 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Dec 31, 2023 | -37.44 Mn |
| Sep 30, 2023 | -14.63 Mn |
| Jun 30, 2023 | -32.87 Mn |
| Mar 31, 2023 | -31.12 Mn |
| Dec 31, 2022 | -30.58 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -28.43 Mn |
| Mar 31, 2022 | -20.85 Mn |
| Dec 31, 2021 | -18.48 Mn |
| Sep 30, 2021 | -20.97 Mn |
| Jun 30, 2021 | -14.31 Mn |